Complete Filing Data
Can-Fite BioPharma Ltd. reported General And Administrative Expense of $3.66 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Can-Fite BioPharma Ltd. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$9.8M | -$7.9M | -$7.6M | -$10.2M | -$12.6M | -$14.4M | -$12.6M | -$6.6M | -$6.4M | -$8.4M |
| Revenue * | $405.0K | $674.0K | $743.0K | $810.0K | $853.0K | $763.0K | $2.0M | $3.8M | ||
| General And Administrative Expense | $3.7M | $3.0M | $3.0M | $3.1M | $3.8M | $3.0M | $3.1M | $3.2M | $2.9M | $2.7M |
| Research And Development Expense | $6.7M | $5.8M | $6.0M | $7.8M | $9.9M | $12.0M | $11.0M | $6.1M | ||
| Operating Income Loss | -$10.0M | -$8.1M | -$8.2M | -$10.1M | -$12.8M | -$14.1M | -$12.0M | -$5.4M | ||
| Nonoperating Income Expense | $250.0K | $561.0K | -$77.0K | $227.0K | -$304.0K | -$618.0K | -$1.2M | |||
| Revenue | $405.0K | $674.0K | $743.0K | $810.0K | $853.0K | $763.0K | $2.0M | $3.8M | ||
| Profit Loss From Operating Activities | -$12.0M | -$5.4M | -$7.2M | -$8.7M | ||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$9.8M | -$7.9M | -$7.6M | -$10.2M | -$12.6M | -$14.4M | -$12.6M | -$6.6M | ||
| Adjustments For Reconcile Profit Loss | -$2.2M | $1.3M | -$542.0K | $25.0K | ||||||
| Profit Loss Attributable To Owners Of Parent | -$9.6M | -$6.6M | -$6.3M | $8.3M | ||||||
| Deferred Revenue Noncurrent | $2.3M | $3.1M | $2.2M | $2.4M | ||||||
| Comprehensive Income Attributable To Owners Of Parent | -$9.6M | -$6.6M | -$5.7M | $8.1M | ||||||
| Comprehensive Income | -$9.6M | -$6.6M | -$5.8M | -$8.3M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $5.6M | $5.4M | $6.2M | $4.5M | $14.4M | $6.1M | $2.4M | $3.0M | $3.0M | ||
| Assets | $9.5M | $9.1M | $10.0M | $9.3M | $20.3M | $9.5M | $8.2M | $8.0M | $7.6M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $703.0K | $547.0K | $1.3M | -$1.4M | -$3.9M | $5.6M | -$918.0K | $110.0K | |||
| Equity | $5.6M | $5.4M | $6.2M | $4.5M | $14.4M | $6.1M | $2.4M | $3.0M | $3.0M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $5.5M | $4.8M | $4.3M | $3.0M | $4.4M | ||||||
| Cash And Cash Equivalents At Carrying Value | $5.5M | $4.8M | $4.3M | $3.0M | $4.4M | $8.3M | $2.7M | $3.6M | $3.5M | ||
| Cash And Cash Equivalents | $2.7M | $3.6M | $3.5M | $8.1M | $16.9M | ||||||
| Retained Earnings Accumulated Deficit | -$176.2M | -$166.4M | -$158.5M | -$150.8M | -$140.7M | -$125.5M | -$110.3M | ||||
| Property Plant And Equipment Net | $5.0K | $27.0K | $29.0K | $42.0K | $47.0K | $50.0K | $36.0K | ||||
| Operating Lease Liability Current | $56.0K | $53.0K | $27.0K | $48.0K | $53.0K | $43.0K | $36.0K | ||||
| Liabilities Noncurrent | $1.2M | $1.6M | $1.7M | $2.3M | $3.1M | $2.2M | $2.5M | ||||
| Liabilities Current | $2.7M | $2.1M | $2.0M | $2.5M | $2.7M | $1.3M | $3.3M | ||||
| Liabilities And Stockholders Equity | $9.5M | $9.1M | $10.0M | $9.3M | $20.3M | $9.5M | $8.2M | ||||
| Assets Current | $9.4M | $9.0M | $9.9M | $9.2M | $20.1M | $9.4M | $7.1M | ||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | ||||
| Accounts Payable Trade Current | $1.2M | $618.0K | $427.0K | $896.0K | $954.0K | $561.0K | $2.2M | ||||
| Operating Lease Right Of Use Asset | $69.0K | $111.0K | $52.0K | $84.0K | $138.0K | $73.0K | $82.0K | ||||
| Operating Lease Liability Noncurrent | $15.0K | $51.0K | $13.0K | $14.0K | $71.0K | $24.0K | $39.0K | ||||
| Prepaid Expense And Other Assets Current | $900.0K | $1.1M | $986.0K | $1.2M | $929.0K | $1.1M | $4.4M | ||||
| Assets Noncurrent | $74.0K | $138.0K | $81.0K | $126.0K | $185.0K | $123.0K | $1.0M | ||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $96.0K | $62.0K | $120.0K | $29.0K | $76.0K | ||||||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $3.0K | $33.0K | $7.0K | $10.0K | |||||||
| Cash Flows From Used In Investing Activities | -$253.0K | -$33.0K | -$29.0K | -$10.0K | |||||||
| Noncurrent Assets | $1.0M | $49.0K | $950.0K | ||||||||
| Cash Flows From Used In Operating Activities | -$10.8M | -$4.2M | -$9.0M | -$8.7M | |||||||
| Adjustments For Increase Decrease In Trade Account Payable | $1.1M | $644.0K | $293.0K | $816.0K | |||||||
| Adjustments For Increase Decrease In Other Operating Payables | -$512.0K | $125.0K | $906.0K | -$100.0K | |||||||
| Adjustments For Increase Decrease In Deferred Income | $146.0K | $1.2M | -$289.0K | $335.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$8.9M | -$7.6M | -$8.4M | -$10.8M | -$9.9M | -$12.1M | -$11.1M | -$4.2M | ||
| Increase Decrease In Other Accounts Payable | $133.0K | $32.0K | $169.0K | -$130.0K | $574.0K | -$279.0K | -$512.0K | $125.0K | ||
| Increase Decrease In Accounts Payable Trade | $543.0K | $191.0K | -$469.0K | -$58.0K | $393.0K | -$1.6M | $1.1M | $644.0K | ||
| Payments To Acquire Property Plant And Equipment | $2.0K | $5.0K | $2.0K | $9.0K | $11.0K | $26.0K | $3.0K | $33.0K | ||
| Net Cash Provided By Used In Investing Activities | -$2.0K | $1.5M | $498.0K | $9.5M | -$14.5M | -$26.0K | -$3.0K | -$33.0K | ||
| Share Based Compensation | $340.0K | $362.0K | $261.0K | $263.0K | $466.0K | $355.0K | ||||
| Increase Decrease In Deferred Revenue | -$405.0K | -$349.0K | -$743.0K | -$810.0K | $1.4M | -$401.0K | $146.0K | $1.2M | ||
| Net Cash Provided By Used In Financing Activities | $9.6M | $6.7M | $9.1M | $20.5M | $17.7M | $10.2M | $4.4M | |||
| Stock Issued During Period Value Share Based Compensation | $263.0K | $398.0K | $317.0K | $270.0K | $253.0K | |||||
| Depreciation Depletion And Amortization | $24.0K | $7.0K | $15.0K | $14.0K | $14.0K | $12.0K | $14.0K | $14.0K | ||
| Increase Decrease In Cash And Cash Equivalents | -$23.0K | $2.0K | -$89.0K | -$4.6M | -$8.8M | |||||
| Increase Decrease In Changes In Fair Value Of Shortterm Investment | -$14.0K | $11.0K | -$229.0K | $162.0K | $11.0K | -$209.0K | -$644.0K | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $10.0K | -$22.0K | $98.0K | -$113.0K | $34.0K | -$23.0K | ||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$195.0K | $109.0K | -$184.0K | $241.0K | -$128.0K | -$4.3M | -$221.0K | $853.0K | ||
| Increase Decrease In Other Operating Liabilities | -$62.0K | -$63.0K | -$8.0K | -$33.0K | ||||||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | $2.0K | -$89.0K | -$83.0K | -$82.0K | ||||||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents In Operating Activies | -$2.0K | $89.0K | $83.0K | $82.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$5.97 | -$10.86 | -$17.92 | -$0.01 | -$0.03 | -$0.04 | -$0.14 | -$0.17 | |||
| Common Stock Shares Authorized | 14.0M | 3.3M | 5.00B | 5.00B | 5.00B | 1.00B | 500.0M | ||||
| Common Stock Shares Outstanding | 2.6M | 994.4K | 1.36B | 815.7M | 815.7M | 463.8M | 120.7M | ||||
| Common Stock Shares Issued | 2.6M | 994.4K | 1.36B | 815.7M | 815.7M | 463.8M | 120.7M | ||||
| Weighted Average Number Of Shares Outstanding Basic | 1.6M | 725.3K | 426.1K | 815.7M | 553.1M | 358.4M | |||||
| Weighted Average Number Of Diluted Shares Outstanding | 1.6M | 725.3K | 426.1K | 815.7M | 553.1M | 358.4M | |||||
| Earnings Per Share Basic | $-5.97 | $-10.86 | $-17.92 | $-0.01 | $-0.03 | $-0.04 | |||||
| Basic And Diluted Earnings Loss Per Share | $-0.11 | $-0.17 | $-0.19 | $0.30 | |||||||
| Common Stock Par Or Stated Value Per Share | $0.25 | $0.25 | $0.25 | $0.25 | $0.25 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value New Issues | $10.0M | $75.0K | $2.4M | $282.0K | ||||
| Finance Income | $3.1M | $51.0K | $633.0K | $374.0K | ||||
| Finance Costs | $693.0K | $1.2M | $621.0K | $55.0K | ||||
| Administrative Expense | $11.0M | $6.1M | $5.1M | $6.1M | ||||
| Adjustments For Sharebased Payments | $385.0K | $535.0K | $192.0K | $309.0K | ||||
| Additional Paid In Capital | $163.6M | $154.2M | $153.9M | $97.4M | $103.4M | |||
| Share Issue Related Cost | $1.4M | $613.0K | $621.0K | |||||
| Increase Decrease Through Sharebased Payment Transactions | $270.0K | $253.0K | $192.0K | $309.0K | ||||
| Interest Paid Received | $72.0K | $51.0K | $69.0K | $89.0K | ||||
| Interest Paid Net | $18.0K | $23.0K | $29.0K | $18.0K | ||||
| Adjustments For Working Capital Total | $989.0K | $1.1M | -$2.0M | -$346.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q2 2020 |
|---|---|
| Stock Issued During Period Value New Issues | $1.6M |
| Finance Income | |
| Finance Costs | |
| Administrative Expense | |
| Adjustments For Sharebased Payments | |
| Additional Paid In Capital | |
| Share Issue Related Cost | |
| Increase Decrease Through Sharebased Payment Transactions | |
| Interest Paid Received | |
| Interest Paid Net | |
| Adjustments For Working Capital Total |
Most recent annual filing with the SEC: March 26, 2026
Data sourced from SEC EDGAR public filings as of August 7, 2026.